Global Colon Cancer Market Overview:
According to the Colon Cancer Alliance, colon cancer is the third most commonly diagnosed and second leading cause of cancer in the United States. Colon cancer/Colorectal Cancer is the cancer of large intestine which forms the lower part of the digestive system. Colon cancer usually begins with small, benign clusters of cells known as adenomatous polyps. If the disease is left untreated, these polyps may result into colon cancer. Therefore, regular screening for polyps through colonoscopy in order to prevent it transforming to colon cancer is recommended. Change in bowel habits or blood in stool are the major symptoms of colon cancer. Colorectal cancer (CRC) accounts for over 9% of all cancer incidences, and it is a major cause of morbidity and mortality throughout the world. CRC is the second most common cause of cancer-related deaths in the United States. Increasing cancer prevention initiatives and technological advancements in Radiology and Chemotherapy are driving the Global Colon Cancer market.
- Rising prevalence of colorectal cancer
- Growing ageing population suffering from colon cancer
- Introduction of new improved therapies and drugs.
- Growing incidences of colon cancer and high pricing of products are attracting pharmaceutical companies to develop and market new products
- Healthcare practitioners are cautioned with the cost-benefit ratio of colon cancer drugs owing to large presence in the market.
- Stringent regulatory norms and side effects of therapies used for the treatment may hamper the growth of the market.
- High unmet demands in emerging economies and lack of adjuvant and non-adjuvant pipeline agents for the treatment of colon cancer is providing opportunity for the market.
- High-cost screening tests or drugs is posing a challenge for the market.
The nature of the vendor landscape is immensely competitive with multinational companies establishing a strong hold over the rest. The players are focused on devising successful strategies, such as competent marketing, expansion of geographical reach, prudent pricing, high investment in R&D, and offering clinical laboratory services. Such as National Nonprofit Colorectal Cancer Alliance is providing a total of USD 625,000 in grants to four researchers, including one advancing personalized treatment options for seeking to understand the root cause of rising colorectal cancer rates in patients under age 50. Product innovation is also viewed as one of the major growth strategies adopted by companies to gain a stronger foothold in the colon cancer market.
Some of the key players profiled in the report are F.Hoffman-La Roche Ltd. (Switzerland), Merck KGaA (Germany), Bayer HealthCare Pharmaceuticals (Germany), Boehringer Ingelheim (Germany), Taiho Pharmaceutical (Japan), Eli Lilly and Company (United States), Pfizer, Inc. (United States), Bedford Laboratories (United States), Teva Pharmaceuticals (Israel), Bermuda Cancer and Health Centre (Bermuda), Akanocure Pharmaceuticals, LLC (United States) and Siamab Therapeutics, Inc (United States). Additionally, following companies can also be profiled that are part of our coverage like Biomoti. Limited (United Kingdom), DNALite Therapeutics (United States), Corporate Health International ApS (United States) and Universal Diagnostics S.L (Spain). Analyst at AdvanceMarketAnalytics see United States Players to retain maximum share of Global Colon Cancer market by 2024. Considering Market by Testing Techniques, the sub-segment i.e. Macroscopy will boost the Colon Cancer market. Considering Market by Targeted Drugs, the sub-segment i.e. Bevacizumab (Avastin) will boost the Colon Cancer market. Considering Market by Pharmacological Class, the sub-segment i.e. Phase 1 clinical trial will boost the Colon Cancer market.
According to ESMO (European Society for Medical Oncology) 2018, In October 2018, Immunotherapy with Nivolumab and low-dose Ipilimumab can become a new first-line treatment in patients with some metastatic colorectal cancers. The drug combination shrank tumors and will have a beneficial effect on survival in patients with microsatellite Instabiliy (MSI)-high metastatic colorectal cancer.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be provided prior to purchase
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Colon Cancer market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Colon Cancer market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Colon Cancer Drug Manufacturers, Government and Regulatory bodies, Pharmaceutical Companies and Distributors, Suppliers and Traders.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.